Jay Lichter - Jun 3, 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Signature
/s/ Jay Lichter
Stock symbol
JANX
Transactions as of
Jun 3, 2024
Transactions value $
-$82,125,000
Form type
4
Date filed
6/5/2024, 07:25 PM
Previous filing
Nov 15, 2023
Next filing
Jun 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Sale -$37.1M -677K -17.15% $54.75 3.27M Jun 3, 2024 By Avalon Ventures XI, L.P. F1, F2
transaction JANX Common Stock Sale -$7.18M -131K -17.15% $54.75 634K Jun 3, 2024 By Avalon BioVentures I, LP F1, F3
transaction JANX Common Stock Sale -$37.9M -692K -17.15% $54.75 3.34M Jun 3, 2024 By Avalon BioVentures SPV I, L.P. F1, F4
holding JANX Common Stock 4.58K Jun 3, 2024 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The shares are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any.
F3 The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
F4 The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
F5 The shares held directly by the Reporting Person prior to the transactions reported herein reflect the receipt of shares pursuant to the pro rata distributions in kind, effected by each of Avalon Ventures, ABV I and ABV SPV to its general partner and limited partners for no additional consideration, and the further pro rata distribution in kind by the general partners of ABV I and ABV SPV, for no additional consideration to their members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership from indirect to direct, which was exempt from reporting pursuant to Rule 16a-13.